Drug intelligence / Profile preview

Avenova Allograft

Development stage: Unknown
Lead developer: BioStem Technologies
Modality: Cell Therapies
Administration: Ophthalmic

Overview

Avenova Allograft is a prescription-only amniotic tissue allograft developed by NovaBay Pharmaceuticals in partnership with BioStem Technologies. It consists of the amnion layer of the placental membrane, measuring 20-50 microns thick, and is processed using the proprietary BioRetain method to preserve the natural integrity of the tissue. The allograft serves as a protective covering to facilitate the repair of ocular surfaces, including the cornea and conjunctiva, in various eye conditions. It was commercially launched in the United States in September 2023 and is available in multiple sizes (8mm, 10mm, and 12mm).

Brand names: Avenova Allograft
Other names: amniotic tissue allograft

Beyond the preview

Go deeper on Avenova Allograft.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Avenova Allograft.

Explore the full profile